| Original language | English (US) |
|---|---|
| Pages (from-to) | 195-197 |
| Number of pages | 3 |
| Journal | Journal of the American College of Cardiology |
| Volume | 78 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jul 13 2021 |
Funding
This research was supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute; and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences and the MESA Early Heart Failure Study (National Heart, Lung, and Blood Institute R01HL127028). Research reported in this publication was supported by the National Research Service Award of the National Institutes of Health T32HL007227. Dr. Shah has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapies, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiora, CVRx, Cytokinetics, Eisai, GlaxoSmithKline, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Sanofi, Shifamed, Tenax, and United Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank the other investigators, staff, and participants of the MESA study for their valuable contributions.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine